It's time to clean up 〈797〉

Hospital Pharmacy

Volumn 41, Issue 11, 2006, Pages 1018-1019

  Sanborn, Michael ^a  

^a BAYLOR HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG MANUFACTURE; EDITORIAL; EVIDENCE BASED PRACTICE; HEALTH CARE POLICY; HEALTH CARE QUALITY; HEALTH CARE SYSTEM; HOSPITAL PHARMACY; MEDICAL PRACTICE; MEDICAL SOCIETY; PATIENT CARE; PATIENT SAFETY; PHARMACIST; PRACTICE GUIDELINE;

EID: 33845347415     PISSN: 00185787     EISSN: None     Source Type: Journal    
DOI: 10.1310/hpj4111-1018     Document Type: Editorial

References (8)

1. Candy TA, Schneider PJ, Pederson CA. Impact of the United States Pharmacopeia chapter 797: results of a national survey. Am J Health-Syst Pharm. 2006;63:1336-1343.
2. Fricker MP, Trissel LA, Rich DS. Turning a new chapter on IV drug compounding safety: USP/NF Chapter 〈797〉. Hosp Pharm. 2004:39;899-920.
3. Kopcha RG. Lack of evidence for ASHP's sterile-products guidelines. Am J Health-Syst Pharm. 2004;61:1445-1446.
4. Thompson CA. USP Chapter 797 enforceable but not often enforced. Am J Health-Syst Pharm. 2006:63;988-990.
5. Thomas M, Sanborn MD, Couldry, R. I.V. admixture contamination rates: Traditional practice site versus a class 1000 cleanroom. Am J Health-Syst Pharm. 2005; 62:2386-2392.
6. Trissel LA, Gentempo RW, Anderson RW, Lajeunesse JD. Using a medium-fill simulation to evaluate the microbial contamination rate for USP medium-risk-level compounding. Am J Health-Syst Pharm. 2005; 62:285-8.
7. Trissel LA, Ogundele AB, Ingram DS, Saenz CA, Gentempo JA. Using medium-fill simulation to establish a benchmark microbiological contamination rate for low-risk-level compounding. Am J Health-Syst Pharm. 2003;60:1853-5.
8. Trapskin PJ, Reagan R, Hite K, Armitstead JA. The implementation of a personnel training and assessment program for new standards in the US pharmacopeia general chapter 〈797〉 pharmaceutical compounding of sterile products. Hosp Pharm. 2006:41;43-48.